Abstract
BackgroundMelanoma outlook has improved due to advances in immunotherapy, specifically anti-PD1 treatment. However, only about 50% of melanoma patients respond, and the barriers to their response remain unclear. Recent studies...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
